CanSino Biologics

CanSino Biologics (simplified Chinese: 康希诺生物; traditional Chinese: 康希諾生物; pinyin: Kāngxīnuò Shēngwù), often abbreviated as CanSinoBIO, is a Chinese vaccine company.[1]

CanSino Biologics Inc.
CanSinoBIO
Native name
康希诺生物
Founded2009 (2009) in Tianjin, China
Founders
  • Yu Xuefeng
  • Zhu Tao
  • Qiu Dongxu
  • Helen Mao Huihua
Headquarters
Tianjin
,
China
Website

History

CanSino Biologics was founded in 2009 in Tianjin by Yu Xuefeng, Zhu Tao, Qiu Dongxu and Helen Mao Huihua.[1]

In July 2018, it filed an application to list on the Hong Kong Stock Exchange.[1] It debuted on 28 March 2019 with an increase of 59%, the highest first day trading gain in Hong Kong since 2017.[2] In August 2020, it completed a secondary offering on Shanghai Stock Exchange's STAR market where it raised 5.2 billion yuan (US$750 million).[3]

Vaccines

The company has a portfolio of vaccines under research including Ad5-EBOV to prevent Ebola and Ad5-nCoV for COVID-19.[1][4] The company has previously collaborated with the National Research Council of Canada (NRC) on vaccine development. The two organizations began collaborating in 2013, and they later worked together to develop an Ebola vaccine.[5][6]

COVID-19 vaccine development
Main article: Ad5-nCoV
See also: COVID-19 vaccine § Clinical trials started in 2020

AD5-nCOV, trade-named Convidicea, is a COVID-19 vaccine candidate being developed by Cansino Biologics. As of December 2020, it is currently in Phase III trials in Argentina, Chile,[7] Mexico,[8] Pakistan,[9] Russia,[10] and Saudi Arabia[11] with over 40,000 people[12] as both a double-dose[12] and single dose administration.[13] Convidicea is a viral vector vaccine similar to AstraZeneca's AZD1222 and Gamaleya's Gam-COVID-Vac which are also in Phase III clinical trials for COVID-19.[14] In November, CanSino said it would begin interim analysis of Phase III results when 50 infection cases are found.[7]

Investors

As of 2018, CanSino Biologics investors included Lilly Asia Ventures, Qiming Venture Partners and SDIC Fund Management.[1]

See also

References
  1. Ng, Eric (25 July 2018). "Chinese vaccine maker CanSino faces tough IPO sell in wake of Changsheng Bio-technology scandal". South China Morning Post. Retrieved 18 April 2020.
  2. Low, Zoe (29 March 2019). "Ebola vaccine maker CanSino Biologics has a plan to take its life-saving treatments well beyond China's domestic market". South China Morning Post. Retrieved 18 April 2020.
  3. Ren, Daniel (13 August 2020). "Covid-19 vaccine maker CanSino soars in Star Market debut". South China Morning Post. Retrieved 15 August 2020.
  4. Pinghui, Zhuang (10 April 2020). "Volunteers needed for second phase of China coronavirus vaccine trial". South China Morning Post. Beijing. Retrieved 18 April 2020.
  5. Canada, National Research Council. "The National Research Council of Canada and CanSino Biologics Inc. announce collaboration to advance vaccine against COVID-19". www.newswire.ca. Retrieved 19 May 2020.
  6. "National Research Council contribution plays key role in newly approved Ebola vaccine". National Research Council Canada. 20 March 2018. The vaccine developed by CanSino is designed to provide protection against the strain of Ebola virus that caused the 2014 outbreak.
  7. Reuters Staff (21 November 2020). "CanSino to test coronavirus vaccine candidate in Argentina and Chile". Reuters. Retrieved 21 November 2020.
  8. "Chinese Covid vaccine trials to be expanded to five more states". Mexico News Daily. 10 November 2020. Retrieved 13 December 2020.
  9. Dawn.com (22 September 2020). "Phase 3 clinical trial for vaccine being developed by China begins in Pakistan". DAWN.COM. Retrieved 13 December 2020.
  10. Reuters Staff (7 December 2020). "Russia approves clinical trials for Chinese COVID-19 vaccine Ad5-Ncov: Ifax". Reuters. Retrieved 13 December 2020.
  11. Reuters Staff (9 August 2020). "CanSino to start Phase III trial of COVID-19 vaccine in Saudi". Reuters. Retrieved 13 December 2020.
  12. "Phase III Trial of A COVID-19 Vaccine of Adenovirus Vector in Adults 18 Years Old and Above - Full Text View - ClinicalTrials.gov". clinicaltrials.gov. Retrieved 21 October 2020.
  13. Yáñez, Patricio Lazcano y Cecilia (15 November 2020). "Así funcionan las cuatro vacunas que se probarán en Chile". La Tercera. Retrieved 17 November 2020.
  14. Zimmer, Carl; Corum, Jonathan; Wee, Sui-Lee (10 June 2020). "Coronavirus Vaccine Tracker". The New York Times. ISSN 0362-4331. Retrieved 12 December 2020.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.